4ce20929-7d04-4c4b-9e3c-de22d237f254
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.300
- HEDGEHOG_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- MITOTIC_SPINDLE+0.200
- MYC_TARGETS_V2+0.200
- NOTCH_SIGNALING+0.200
- PROTEIN_SECRETION+0.200
- MYC_TARGETS_V1+0.100
- SPERMATOGENESIS+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- ALLOGRAFT_REJECTION-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- COMPLEMENT-0.400
- MTORC1_SIGNALING-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- UV_RESPONSE_UP-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5L8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.851 |
| 2 | TCGA-A1-A0SB-01A-11R-A144-07 | — | A | 0.845 |
| 3 | TCGA-A2-A1FV-01A-11R-A13Q-07 | — | B | 0.823 |
| 4 | TCGA-A8-A091-01A-11R-A00Z-07 | — | B | 0.822 |
| 5 | TCGA-A7-A0D9-01A-31R-A056-07 | — | B | 0.819 |
| 6 | TCGA-A8-A08T-01A-21R-A00Z-07 | — | B | 0.814 |
| 7 | SRR8613756 | — | E | 0.814 |
| 8 | SRR8518374 | — | E | 0.812 |
| 9 | R274 | — | — | 0.809 |
| 10 | ca7ac1e1-4c44-40a5-8094-eeebc0c2c5a2 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |